EGFR mutations

Test Your Knowledge

Quiz: What Combo Therapy Yields Benefit in Patients with EGFR Mutated Advanced NSCLC?

08/03/2021

The combination of first-generation EGFR-TKIs and ______ achieves a satisfactory PFS, ORR, DCR, and well-tolerated toxicity in advanced NSCLC patients with EGFR mutations.

The combination of...

08/03/2021

Oncology

News

EGFR-TKIs Exhibit Safety and Tolerability in Patients with NSCLC

07/22/2021

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in combination with chemotherapy were studied for safety variables in patients with advanced non-small-cell lung cancer (NSCLC) and sensitive EGFR mutations.

Epidermal growth factor...

07/22/2021

Oncology

Research Reports

Cost-Effectiveness of Afatinib Versus Erlotinib in the First-line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With EGFR Exon 19 Deletion Mutations

05/06/2016

Jonathan Graham, BS

Stephanie Earnshaw, PhD

Jonathan Lim, BS, MS, MSc

Rakesh Luthra, MS

Rohit Borker, PhD

Abstract: A decision model was developed to compare the cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non–small cell lung cancer (NSCLC) with epidermal growth...

...

05/06/2016

Journal of Clinical Pathways